Helmholtz

MDC researcher Jan Philipp Junker and his collaborator Maria Colomé-Tatché at Helmholtz Center Munich have received a €200,000 grant to improve big data processing to better understand how gene networks are wired together during development and disease.

Anton Henssen works as a paediatrician and researches rare tumours at the Max Delbrück Center. Incidentally, he’s also a conceptual artist with way more to his paintings than meets the eye.

Together with Charité and WIS, the MDC is establishing the German-Israeli Helmholtz International Research School iNAMES – an interdisciplinary training program for PhD students interested in imaging.

Enabling new applications, learning from one another, linking research fields, harnessing synergies and cumulative experience in imaging processes for all: this is what the new Helmholtz Imaging Platform (HIP), coordinated by the MDC, DKFZ and DESY, promises.

LifeTime is one of the six winners of an EU-wide competition in which ambitious and forward-looking research projects are selected and funded. This was officially announced by the European Commission on Tuesday. The coordinators of LifeTime in Berlin and Paris were pleased that they can now begin the actual work. Chancellor Merkel praised the initiative.

Translating research findings into viable commercial applications plays a key role in solving societal problems. The Helmholtz Association therefore supports projects that are particularly promising in this regard through the Helmholtz Validation Fund (HVF).

16 Helmholtz Association Centers have terminated their license agreements with scientific publisher Elsevier effective by the end of 2017. One of these Centers is the Max Delbrück Center for Molecular Medicine (MDC).

Shadi Hussein works as an intern within the Helmholtz Initiative for Integration of Refugees of the MDC, HZB and HGF in the group of Annette Hammes.

Transferring MDC inventions into pharmaceuticals and therapies – this is the mission driving MDC’s department of technology transfer. Their latest achievement, a pharmaceutical substance for atrial fibrillation developed by MDC spin-off OMEICOS Therapeutics, is now entering clinical trials.